0001437749-23-008737 | 10-K | XBRL Viewer | Acelrx Pharmaceuticals INC

Print Document View Excel Document

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2022	Mar. 20, 2023	Jun. 30, 2022
Document Information [Line Items]
Entity Central Index Key	0001427925
Entity Registrant Name	ACELRX PHARMACEUTICALS INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity File Number	001-35068
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	41-2193603
Entity Address, Address Line One	25821 Industrial Boulevard, Suite 400
Entity Address, City or Town	Hayward
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94545
City Area Code	650
Local Phone Number	216-3500
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	ACRX
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 35,604,258
Entity Common Stock, Shares Outstanding		10,918,452
Auditor Name	WithumSmith+Brown, PC
Auditor Location	San Francisco, California
Auditor Firm ID	100

Consolidated Balance Sheets - USD ($)
$ in Thousands

Dec. 31, 2022

Dec. 31, 2021

Current Assets:

Cash and cash equivalents

$ 15,275

$ 7,663

^[1]

Restricted cash

5,000

Short-term investments

495

38,967

^[1]

Accounts receivable, net

309

160

^[1]

Inventories, net

1,178

1,111

^[1]

Prepaid expenses and other current assets

2,309

2,588

^[1]

Total current assets

24,566

50,489

^[1]

Operating lease right-of-use assets

3,595

4,302

^[1]

Property and equipment, net

10,261

15,928

^[1]

In-process research and development asset

8,819

Other assets

246

2,174

^[1]

Restricted cash, net of current portion

5,000

Total assets

47,487

77,893

^[1]

Current Liabilities:

Accounts payable

2,040

2,121

^[1]

Accrued and other liabilities

4,266

6,524

^[1]

Long-term debt, current portion

5,763

8,796

^[1]

Operating lease liabilities, current portion

1,701

1,068

^[1]

Total current liabilities

13,770

18,509

^[1]

Long-term debt, net of current portion

5,007

^[1]

Deferred revenue, net of current portion

1,036

1,151

Operating lease liabilities, net of current portion

2,959

3,750

^[1]

Warrant liability

7,098

85,288

^[1]

Other long-term liabilities

810

^[1]

Total liabilities

25,673

113,786

^[1]

Commitments and Contingencies

Common stock, $0.001 par value—200,000,000 shares authorized as of December 31, 2022 and 2021; 8,243,680 and 6,840,967 shares issued and outstanding as of December 31, 2022 and 2021, respectively

^[2]

^[1]

Additional paid-in capital

^[2]

447,635

437,684

^[1]

Accumulated deficit

^[2]

(425,829)

(473,584)

^[1]

Total stockholders’ equity (deficit)

^[2]

21,814

(35,893)

Total Liabilities and Stockholders’ Equity (Deficit)

$ 47,487

$ 77,893

[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.
[2]	Adjusted to give retroactive effect to a 1-for-20 reverse stock split effective as of 5:01 p.m. Eastern Time on October 25, 2022.

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	8,243,680	6,840,967
Common stock, shares outstanding (in shares)	8,243,680	6,840,967

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Revenue	$ 1,771	$ 2,818
Operating costs and expenses:
Cost of goods sold	2,591	3,753
Research and development	5,193	4,095
Selling, general and administrative	25,672	30,935
Impairment of property and equipment	4,948	0
Total operating costs and expenses	38,404	38,783
Loss from operations	(36,633)	(35,965)
Other income:
Interest expense	(1,153)	(2,291)
Interest income and other income, net	366	124
Non-cash interest income on liability related to sale of future royalties	1,136	3,038
Gain on extinguishment of liability related to the sale of future royalties	84,052	0
Total other income	84,401	871
Net income (loss) before provision for income taxes	47,768	(35,094)
Provision for income taxes	13	5
Net income (loss)	47,755	(35,099)
Deemed dividend related to Series A Redeemable Convertible Preferred Stock	(186)	0
Income allocated to participating securities	(5,240)	0
Net income (loss) attributable to Common Shareholders, basic	$ 42,329	$ (35,099)
Net income (loss) per share of common stock, basic (in dollars per share)	$ 5.73	$ (5.86)
Shares used in computing net income (loss) per share of common stock, basic–(Note 16) (in shares)	7,385,348	5,993,013
Net income (loss) attributable to Common Shareholders, diluted	$ 42,342	$ (35,099)
Net income (loss) per share of common stock, diluted (in dollars per share)	$ 5.72	$ (5.86)
Shares used in computing net income (loss) per share of common stock, diluted –(Note 16) (in shares)	7,406,986	5,993,013
Product [Member]
Revenue:
Revenue	$ 1,771	$ 1,005
Contract and Other Collaboration [Member]
Revenue:
Revenue	$ 0	$ 1,813

Consolidated Statements of Stockholders' Deficit - USD ($)
$ in Thousands